Pharm'Up 
Zydus Lifesciences Limited showcased a solid performance for the quarter ending June 30, 2025, with notable growth across various regions and significant contributions from its innovation-led strategies. The company reported revenue from operations at Rs. 65,737 million, reflecting a 6% year-on-year increase and a slight 0.7% uptick from the prior quarter. Net profit reached Rs. 14,668 million, marking a 3% rise compared to the same quarter last year and a substantial 25.3% jump from Q4 FY25.
Earnings before interest, tax, depreciation, and amortisation (EBITDA) stood at Rs. 20,885 million, with a margin of 31.8%. Although this was marginally below last year’s 33.6%, it showed improvement over the previous quarter’s 32.6%. The company allocated Rs. 4,856 million to research and development, equating to 7.4% of revenues, underscoring its commitment to advancing its innovation pipeline. Capital expenditure for the period was Rs. 4,020 million.
The India business, encompassing formulations and consumer wellness, generated Rs. 23,744 million, a 6% year-on-year increase, contributing 37% to total revenues. Prescription formulations accounted for Rs. 15,195 million, with an 8% growth driven by strong demand in chronic therapy areas like oncology, cardiology, respiratory care, anti-infectives, and pain management. The consumer wellness segment recorded Rs. 8,549 million in sales, up 2%, with double-digit growth in non-seasonal brands. Organized trade channels performed well, and e-commerce contributed 14.5% to wellness revenues.
The US formulations business, the largest revenue contributor, delivered Rs. 31,817 million, a 2.9% rise year-on-year, making up nearly half of consolidated sales. In the quarter, Zydus launched three new products in the US, filed three abbreviated new drug applications (ANDAs), and received six product approvals, including two tentative ones. International formulations sales soared 37% year-on-year to Rs. 7,265 million, highlighting the company’s expanding presence in emerging markets. The active pharmaceutical ingredients (API) segment reported revenues of Rs. 1,575 million, an 11.3% increase, while the alliances and others segment dropped 28% to Rs. 269 million.
Operationally, Zydus received USFDA Establishment Inspection Reports for its API facilities in Ankleshwar and Dabhasa following inspections earlier this year, reinforcing its regulatory compliance. Innovation remained a priority, with significant progress including the initiation of Phase II(b) trials in the US for Usnoflast, a novel NLRP3 inflammasome inhibitor for amyotrophic lateral sclerosis (ALS), which also earned USFDA Fast Track and Orphan Drug designations. Additionally, the company secured DCGI marketing approval for its biosimilars Rituximab and Aflibercept.
Looking forward, Managing Director Dr. Sharvil Patel noted that the results demonstrate “disciplined execution” and align with the company’s FY26 goals. He emphasized that continued investments in innovation and market expansion are poised to create new opportunities for sustainable growth in the upcoming quarters.
About the Author
